EU ethics group issues view on stem cell patents
This article was originally published in Clinica
Executive Summary
The European Ethics Group, which has been looking into the patentability of stem cell lines, has recommended to the European Commission that it should be possible to patent both adult stem cell and embryonic stem cell lines under certain conditions. But it cautions against patenting abuse, where over-patenting could result in access to diagnostics and treatment could be blocked.